Atlas Trials

The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks

Clinical trial NCT03931239 · COMPLETED

Trial details

NCT number
NCT03931239
Sponsor
Vabiotech
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
DiphtheriaTetanusPertussisHepatitis BHaemophilus Influenzae Type B
Start date
2018-03-01
Primary completion
2018-06-30
Enrollment
222

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.